GlassScriptPhysician profile
Juan Ricaurte
NPI 1427046341
$3,668.44
in general payments reported to CMS, 2019-2025
13 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $659 · 2021: $384 · 2022: $305 · 2023: $623 · 2024: $447 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Education: $1.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.88 |
| Education | $1.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $1,382.53 | 2020-2025 | Fetroja |
| Gilead Sciences, INC. | $721.25 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $601.26 | 2019-2021 | |
| Allergan, INC. | $379.03 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $238.75 | 2019-2020 | |
| Viiv Healthcare Company | $185.38 | 2019-2023 | Rukobia, Dovato |
| Tetraphase Pharmaceuticals, INC. | $45.76 | 2019 | |
| Theratechnologies INC. | $28.08 | 2023 | Egrifta, Trogarzo |
| Nabriva Therapeutics, Plc | $20.80 | 2020 | |
| Emd Serono, INC. | $20.27 | 2020 | |
| Vyera Pharmaceuticals, LLC | $18.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.18 | 2019 | |
| Napo Pharmaceuticals INC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Ricaurte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.